Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

SWOG

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Established: 1956-01-01

Employees: 101

Market Cap: -

Website: http://www.swog.org

Clinical Trials

Making Informed Choices on Incorporating Chemoprevention Into Care (MiCHOICE)

Not Applicable

Active, not recruiting

Conditions: Atypical Hyperplasia of the Breast
Pleomorphic Lobular Breast Carcinoma In Situ
Lobular Breast Carcinoma In Situ

First Posted Date: 2020-08-03

Last Posted Date: 2025-05-09

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 412

Registration Number: NCT04496739

Locations: 🇺🇸
Kaiser Permanente-Deer Valley Medical Center, Antioch, California, United States
🇺🇸
UC Irvine Health Cancer Center-Newport, Costa Mesa, California, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States

and more 94 locations

A Study of MiRNA 371 in Patients with Germ Cell Tumors

Active, not recruiting

Conditions: Germ Cell Tumor
Metachronous Malignant Neoplasm
Seminoma
Stage I Testicular Cancer AJCC V8
Stage IA Testicular Cancer AJCC V8
Stage IB Testicular Cancer AJCC V8
Stage is Testicular Cancer AJCC V8

First Posted Date: 2020-06-17

Last Posted Date: 2025-02-26

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 956

Registration Number: NCT04435756

Locations: 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸
Kingman Regional Medical Center, Kingman, Arizona, United States
🇺🇸
University of Arizona Cancer Center-Orange Grove Campus, Tucson, Arizona, United States

and more 421 locations

Study to Test AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Phase 2

Recruiting

Conditions: Refractory T Acute Lymphoblastic Leukemia
Recurrent T Acute Lymphoblastic Leukemia

Interventions: Drug: AKR1C3-activated Prodrug OBI-3424

First Posted Date: 2020-03-19

Last Posted Date: 2024-11-07

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 39

Registration Number: NCT04315324

Locations: 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
Kingman Regional Medical Center, Kingman, Arizona, United States
🇺🇸
PCR Oncology, Arroyo Grande, California, United States

and more 113 locations

Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial)

Phase 2

Withdrawn

Conditions: Lung Squamous Cell Carcinoma
Recurrent Lung Carcinoma
Stage IV Lung Cancer AJCC v8
Stage IVA Lung Cancer AJCC v8
Stage IVB Lung Cancer AJCC v8

Interventions: Drug: Dexamethasone
Drug: Docetaxel
Biological: Ramucirumab
Drug: Sapanisertib

First Posted Date: 2020-02-13

Last Posted Date: 2020-11-20

Lead Sponsor: SWOG Cancer Research Network

Registration Number: NCT04267913

Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)

Phase 2

Active, not recruiting

Conditions: Recurrent Lung Non-Small Cell Carcinoma
Stage IV Lung Cancer AJCC v8
Stage IVA Lung Cancer AJCC v8
Stage IVB Lung Cancer AJCC v8

Interventions: Drug: Selpercatinib

First Posted Date: 2020-02-13

Last Posted Date: 2024-11-28

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 124

Registration Number: NCT04268550

Locations: 🇺🇸
Fairbanks Memorial Hospital, Fairbanks, Alaska, United States
🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸
Kaiser Permanente-Anaheim, Anaheim, California, United States

and more 303 locations

Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers

Phase 2

Recruiting

Conditions: Stage IIIA Small Intestinal Adenocarcinoma AJCC v8
Stage IV Small Intestinal Adenocarcinoma AJCC v8
Metastatic Small Intestinal Adenocarcinoma
Stage III Small Intestinal Adenocarcinoma AJCC v8
Stage IIIB Small Intestinal Adenocarcinoma AJCC v8

Interventions: Drug: Paclitaxel
Drug: Fluorouracil
Biological: Ramucirumab
Drug: Irinotecan
Drug: Irinotecan Hydrochloride
Drug: Leucovorin
Drug: Leucovorin Calcium

First Posted Date: 2019-12-20

Last Posted Date: 2024-08-16

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 94

Registration Number: NCT04205968

Locations: 🇺🇸
Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
🇺🇸
Anchorage Radiation Therapy Center, Anchorage, Alaska, United States
🇺🇸
Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States

and more 459 locations

Testing Diet Intervention Versus Non-Diet Intervention for Management of Bowel Symptoms in Rectal Cancer Survivors

Phase 2

Completed

Conditions: Rectal Carcinoma
Rectosigmoid Carcinoma

First Posted Date: 2019-12-20

Last Posted Date: 2024-05-01

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 95

Registration Number: NCT04205955

Locations: 🇺🇸
Banner University Medical Center - Tucson, Tucson, Arizona, United States
🇺🇸
University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
🇺🇸
UC Irvine Health Cancer Center-Newport, Costa Mesa, California, United States

and more 223 locations

S1916 Digital Medicine Program for Pain Control in Cancer Patients

Not Applicable

Terminated

Conditions: Metastatic Cancer

Interventions: Drug: Oxycodone/acetaminophen 5/325 mg
Device: Proteus digital medicine program

First Posted Date: 2019-12-11

Last Posted Date: 2023-06-27

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 2

Registration Number: NCT04194528

Locations: 🇺🇸
Decatur Memorial Hospital, Decatur, Illinois, United States
🇺🇸
Carle Cancer Center NCORP, Urbana, Illinois, United States
🇺🇸
Montana Cancer Consortium, Billings, Montana, United States

and more 2 locations

Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)

Phase 2

Active, not recruiting

Conditions: Stage IVB Lung Cancer AJCC v8
Recurrent Lung Non-Squamous Non-Small Cell Carcinoma
Stage IV Lung Cancer AJCC v8
Advanced Lung Non-Squamous Non-Small Cell Carcinoma
Stage IVA Lung Cancer AJCC v8

Interventions: Drug: Avelumab
Drug: Talazoparib
Drug: Talazoparib Tosylate

First Posted Date: 2019-11-22

Last Posted Date: 2024-06-04

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 47

Registration Number: NCT04173507

Locations: 🇺🇸
University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States
🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸
Kaiser Permanente-Anaheim, Anaheim, California, United States

and more 322 locations

S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer

Phase 3

Recruiting

Conditions: Lung Small Cell Carcinoma
Limited Stage Lung Small Cell Carcinoma
Extensive Stage Lung Small Cell Carcinoma

First Posted Date: 2019-11-07

Last Posted Date: 2025-05-25

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 668

Registration Number: NCT04155034

Locations: 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
Katmai Oncology Group, Anchorage, Alaska, United States
🇺🇸
Fairbanks Memorial Hospital, Fairbanks, Alaska, United States

and more 443 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy